stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) EBITDA
Genmab A/S Sponsored ADR's EBITDA for fiscal 2025 was $1.1B, up 10.1% from $1.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from $155.2M (fiscal 2016) to $1.1B (fiscal 2025) — the current reading is the highest in ten years. Genmab A/S Sponsored ADR ranks 6th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.1B | 10.08% |
| FY2024 | $1.0B | 26.56% |
| FY2023 | $815.4M | (14.29%) |
| FY2022 | $951.4M | 83.10% |
| FY2021 | $519.6M | (48.39%) |
| FY2020 | $1.0B | 141.87% |
| FY2019 | $416.3M | 79.03% |
| FY2018 | $232.5M | 2.11% |
| FY2017 | $227.7M | 46.73% |
| FY2016 | $155.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $401.0M | 91.87% |
| Mar 2026 | $209.0M | 164.56% |
| Dec 2025 | $79.0M | (83.44%) |
| Sep 2025 | $477.0M | 26.86% |
| 27 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| GMAB Genmab A/S Sponsored ADR | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| INCY Incyte Corporation compare | $724.9M |
| INSM Insmed, Inc. compare | −$531.4M |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement